The stock of Signal Genetics Inc (NASDAQ:SGNL) is a huge mover today! About 584,827 shares traded hands or 2554.93% up from the average. Signal Genetics Inc (NASDAQ:SGNL) has declined 6.80% since April 18, 2016 and is downtrending. It has underperformed by 11.23% the S&P500.
The move comes after 9 months positive chart setup for the $8.20M company. It was reported on Nov, 18 by Barchart.com. We have $19.38 PT which if reached, will make NASDAQ:SGNL worth $5.74 million more.
Signal Genetics Inc (NASDAQ:SGNL) Ratings Coverage
Out of 3 analysts covering Signal Genetics (NASDAQ:SGNL), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Signal Genetics has been the topic of 3 analyst reports since September 23, 2015 according to StockzIntelligence Inc. The rating was maintained by Chardan Capital Markets on Wednesday, September 23 with “Buy”. The firm has “Buy” rating by Rodman & Renshaw given on Friday, January 8. H.C. Wainwright initiated it with “Buy” rating and $4 target price in Friday, January 8 report.
According to Zacks Investment Research, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment increased to 1 in 2016 Q2. Its up 0.43, from 0.57 in 2016Q1. The ratio improved, as 4 funds sold all Signal Genetics Inc shares owned while 3 reduced positions. 4 funds bought stakes while 0 increased positions. They now own 715,503 shares or 8.06% less from 778,231 shares in 2016Q1.
Vanguard Grp has 0% invested in the company for 102,575 shares. The Minnesota-based Perkins Management has invested 0.03% in Signal Genetics Inc (NASDAQ:SGNL). Advisory Svcs, a Massachusetts-based fund reported 39,250 shares. The Illinois-based Hightower Advisors Ltd has invested 0% in Signal Genetics Inc (NASDAQ:SGNL). Moreover, Citadel Limited Liability Corp has 0% invested in Signal Genetics Inc (NASDAQ:SGNL) for 34,787 shares. Moreover, Creative Planning has 0% invested in Signal Genetics Inc (NASDAQ:SGNL) for 13,165 shares. Blackrock Fund last reported 1,341 shares in the company. Bancorp Of America Corporation De accumulated 18 shares or 0% of the stock. Susquehanna Group Inc Limited Liability Partnership accumulated 27,003 shares or 0% of the stock. Renaissance Technologies Limited Company last reported 15,200 shares in the company.
Another recent and important Signal Genetics Inc (NASDAQ:SGNL) news was published by Marketwatch.com which published an article titled: “Virtual Stock Exchange” on June 14, 2014.
SGNL Company Profile
Signal Genetics, Inc., incorporated on December 8, 2010, is a commercial stage, molecular genetic diagnostic company. The Firm is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.